Aleniglipron Shows 16.2% Weight Loss at 72 Weeks, CEO Touts Safety and Cost Edge
GPCR sits 62% above its 52-week low of $22.7.
Summary
Structure Therapeutics reported Phase 2 extension data for its oral GLP-1 aleniglipron, showing up to 16.2% mean weight loss at 72 weeks with no plateau and low discontinuations after a lower starting dose. CEO Ray Stevens highlighted no drug-related liver injury and lower manufacturing costs versus Novo Nordisk and Lilly. This adds specific efficacy and safety details to the positive clinical update from September 8, reinforcing the drug's competitive profile in the obesity market. The data supports the company's Phase 3 plans and could strengthen its positioning against established injectable GLP-1s.
At the time of this announcement, GPCR was trading at $36.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $22.70 to $94.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.